WO1983000147A1 - Analogues de l'acide 8-anylino naphtalene-1-sulfonique - Google Patents

Analogues de l'acide 8-anylino naphtalene-1-sulfonique Download PDF

Info

Publication number
WO1983000147A1
WO1983000147A1 PCT/AU1982/000097 AU8200097W WO8300147A1 WO 1983000147 A1 WO1983000147 A1 WO 1983000147A1 AU 8200097 W AU8200097 W AU 8200097W WO 8300147 A1 WO8300147 A1 WO 8300147A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
ans
carbon atoms
strong acid
anion
Prior art date
Application number
PCT/AU1982/000097
Other languages
English (en)
Inventor
Prince Charles Hospital Development Centre ... The
Original Assignee
Duffy, Patrick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duffy, Patrick filed Critical Duffy, Patrick
Publication of WO1983000147A1 publication Critical patent/WO1983000147A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding

Definitions

  • THIS INVENTION relates to new analogues of 8-anilino naphthalene -1- sulphonic acid, processes for their preparation, and their use in enzyme i ⁇ munoassay techniques.
  • the known organic chemical 8-anilino naphthalene-1-sulphonic acid (ANS) has been widely used as an additive to reagents used in the technique known as radio-immuno assay to prevent interferences resulting from the binding of serum protein constituents to the drug or hor mone ligand/ligand-tracer which binding interferes with the specific binding of such ligand/ligand-tracer to the specific binding antibody used in the proceedure.
  • proceedures such as the radio-immuno assay for thyroid hormones such as thyroxine e.g. Chopra, I.J. 'A radioimmunoassay for the measurement of thyroxine in unextracted serum'. J. Clin.
  • the use of ANS provides a specific benefit to the assays in providing marked improvements in the speed of the assay as well as in the specificity of the assay. The reason for this improvement has been extensively studied as for example Cheng S. et al. Biochemistry 16 (1977) p3707 in which ANS binding to pre-albumin was studied; and Nilsson S.F. and Peterson P.A.
  • This invention relates to a chemical modification of the molecular structure of ANS to form an analogue such that the analogue retains the protein binding characteristics of ANS but does not possess the light absorbance or fluorescence properties, or the instability to light characteristic of ANS which inhibits its use with non-isotopic immunoassay techniques.
  • ANS The structure of ANS is as shown in figure 1 and it would appear to be the peculiar nature of the configuration of the three aromatic rings that confers on the molecule the ability to be tightly bound to thyroid binding globulin, pre-albumin, and also the binding to albumin.
  • the sulphonate group causes the molecule to be water soluble. From consideration of the structure it would appear that the lone pair of electrons present on the anilino nitrogen will allow electron conjugation to occur throughout the three aromatic rings. It is usual for such conjugation to be associated with shifts in light absorbance to wavelengths greater than 300 nm, and this conjugation would also appear to be associated with the known fluorescent characteristics of ANS,
  • the structure of the ANS analogues may have the following formula as shown in figure 2.
  • R 1 may be H or an alkyl group of from U8 carbon atoms
  • Y may be H or an aliphatic of from 1-8 carbon atoms
  • n is 1 or 2
  • m is 1 or 2
  • A is the anion of a strong acid.
  • R 1 is lower alkyl of 1-4 carbon atoms and is more preferably methyl or ethyl. Most preferably however R 1 is H.
  • Y is lower alkyl of 1-4 carbon atoms and is more preferably methyl or ethyl.
  • a preferred compound of the invention is where R 1 is H, R 2 is -COCH 3 and A is sulphate thereby providing the compound N-acetyl-8- anilinium-naphthalene 1-sulphonic acid sulphate, (hereinafter referred to as NA-ANS).
  • A is an anion of a strong acid and may include chloride or nitrate but is most preferably sulphate.
  • a compound of Figure 2 wherein R 2 is H and R 1 is H may be prepared by reaction of ANS with a strong acid under appropriate conditions. Host preferably the acid in sulphuric acid and the reaction occurs at room temperature.
  • acetic anhydride trifluoroacetic anhydride, acetyl chloride or a thioacylating agent of 1-8 carbon atoms (e.g.a sulphenyl chloride or thioanhydrides) in the presence of a strong acid which is most preferably anhydrous sulphuric acid at room temperature.
  • a strong acid which is most preferably anhydrous sulphuric acid at room temperature.
  • a suitable alkylating agent is alkyl halide (eg alkyl chloride).
  • the synthesis of such an analogue, N-acetyl-8-anilinium- naphthalene-1-sulphonic acid sulphate, (NA-ANS) will be detailed and this analogue will be shown to retain the protein binding characteristics of ANS while the above noted light and fluorescent detrimental properties of ANS are significantly altered.
  • NA-ANS is able to be successfully utilised in non-isotopic immunoassays in a manner analogous to the use of ANS itself in radio-irtnunoassays and such uses will be detailed. Synthesis of NA-ANS
  • NA-ANS in non-isotopic immunoassays was demonstrated by way of example by its use in non-homongenous enzyme immunoassays for thyroxine, triiodo-thyronine, digoxin and theophylline. It will be evident to those skilled in the art that such use and observed benefits are not exclusive to the particular non-isotopic immunoassay procedure described and utilised herein but are equally applicable to other enzyme and non-enzyme non-isotopic immunoassay procedures.
  • b-galactosidase thyroxine, serum thyroxine, and anti-thyroxine antibody framents were incubated in buffer for thirty minutes at room temperature, solid phase precipitating antibody added, and the mixture incubated for a further 30 minutes. The mixture is then centrifuged at 2000 rpm for 5 minutes on a bench centrifuge and the supernatant assayed for residual enzyme activity.
  • Reagents 1. b-galactosidase thyroxine solution containing 200 nM moles thyroxine and 130 nM moles protein. 2. Anti-thyroxine antibody.
  • Fab derivatives of anti thyroxine gamma globulin sufficient to give 60% binding of b-galactosidase thyroxine in assay. 3. Solid phase precipitating antibody. Sepharose-anti Fab antibody diluted in buffer to give 100% binding of Fab in the assay.
  • the procedure of the assay is as follows and all steps are carried out at room temperature. Duplicate assays were carried out on all samples.
  • (a) Make a dilution of enzyme thyroxine by taking 1 part of enzyme and 134 parts of buffer. Pipette in order into a '0.25' ml conical autoanalyser cup 200uL of the diluted enzyme-thyroxine, 20uL of sample or calibrator, and 50uL of the diluted Fab antibody. Also prepare a 'total* enzyme activity tube using 200uL of enzyme ligand in buffer, 20 uL of a calibrator, with 50 uL of buffer, and treat similarly to the other tubes.
  • Triiodothyronine Assay An assay for triiodothyronine was similarly established using methods similar to that described above with the exception that the buffer used was borate 0.05M pH 8.6 and the use of appropriate Fab fragments directed against triiodothyronine and a b-galactosidase triiodothyronine derivative. In an analogous manner to the above similar binding curves in the presence and absence of NA-ANS were observed.
  • the subject invention provides the benefits to non-istopic immunoassays similar to that observed with ANS in isotopic immunoassays and allows for improved, simple and rapid assays by its inclusion in the assay.
  • the previous limitations on such assays by the chemical and physical properties of ANS detrimental to such assays have been circumscribed by the altered properties observ ed with the alterations to the ANS molecule.
  • the invention also includes within its scope a process for the determination of a component of the reaction between a bindable substance selected from the group consisting of an antigen, a hapten, and a low molecular substance and a protein capable of binding said Tnndable substance specifically, said protein being selected from the group consisting of an antibody and a specific binding protein characterized in that said reaction additionally includes as a reaction component a compound as defined in Figure 1 wherein said compound binds to serum proteins present in the reaction system thereby inhibiting binding of said bindable substance to said serum proteins and thus improving the specificity of said process for determination of said component.
  • the abovementioned process is more applicable to non isotopic immunoassay procedures such as enzyme immunoassays which may be homogeneous or non-homogeneous.

Abstract

Nouveaux analogues de l'acide 8-anylino naphtalène-1-sulfonique, leurs procédés de préparation et leur utilisation dans des techniques d'analyses immunologiques enzymatiques. L'invention se réfère notamment aux composés de la formule$(10,)$où R1 est H ou un groupe aliphatique composé de 1 à 8 atomes de carbone, R2 est H ou C (Y) = X où X est O ou S, Y est H ou un groupe aliphatique composé de 1 à 8 atomes de carbone, n est 1 ou 2, m est 1 ou 2 et A est un anion d'un acide fort.
PCT/AU1982/000097 1981-06-26 1982-06-18 Analogues de l'acide 8-anylino naphtalene-1-sulfonique WO1983000147A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPE9477810626 1981-06-26
AUPE947781 1981-06-26

Publications (1)

Publication Number Publication Date
WO1983000147A1 true WO1983000147A1 (fr) 1983-01-20

Family

ID=3769112

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU1982/000097 WO1983000147A1 (fr) 1981-06-26 1982-06-18 Analogues de l'acide 8-anylino naphtalene-1-sulfonique

Country Status (3)

Country Link
EP (1) EP0082156A4 (fr)
JP (1) JPS58501073A (fr)
WO (1) WO1983000147A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988009505A1 (fr) * 1987-05-21 1988-12-01 P B Diagnostic Systems, Inc. Systeme d'analyse diagnostique biologique
EP0674174A2 (fr) * 1994-03-25 1995-09-27 Johnson & Johnson Clinical Diagnostics, Inc. Dispositif d'analyse multicouches pour la détermination de salicylate
WO1998003876A1 (fr) * 1996-07-18 1998-01-29 Behringwerke Aktiengesellschaft Reactif pour le dosage de l'acide mycophenolique
WO1998003877A1 (fr) * 1996-07-18 1998-01-29 Behringwerke Aktiengesellschaft Reactifs pour dosage de ligands

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4091013A (en) * 1975-08-07 1978-05-23 Bayer Aktiengesellschaft Process for preparing 1-amino-naphthalene-7-sulphonic acid
GB1521643A (en) * 1976-01-30 1978-08-16 Ciba Geigy Ag Process for the manufacture of naphthylaminosulphonic acids

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4091013A (en) * 1975-08-07 1978-05-23 Bayer Aktiengesellschaft Process for preparing 1-amino-naphthalene-7-sulphonic acid
GB1521643A (en) * 1976-01-30 1978-08-16 Ciba Geigy Ag Process for the manufacture of naphthylaminosulphonic acids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0082156A4 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988009505A1 (fr) * 1987-05-21 1988-12-01 P B Diagnostic Systems, Inc. Systeme d'analyse diagnostique biologique
EP0293971A1 (fr) * 1987-05-21 1988-12-07 PB Diagnostic Systems, Inc. Système d'essai biologique et diagnostique
EP0674174A2 (fr) * 1994-03-25 1995-09-27 Johnson & Johnson Clinical Diagnostics, Inc. Dispositif d'analyse multicouches pour la détermination de salicylate
EP0674174A3 (fr) * 1994-03-25 1996-02-28 Johnson & Johnson Clin Diag Dispositif d'analyse multicouches pour la détermination de salicylate.
WO1998003876A1 (fr) * 1996-07-18 1998-01-29 Behringwerke Aktiengesellschaft Reactif pour le dosage de l'acide mycophenolique
WO1998003877A1 (fr) * 1996-07-18 1998-01-29 Behringwerke Aktiengesellschaft Reactifs pour dosage de ligands
US6159698A (en) * 1996-07-18 2000-12-12 Dade Behring Marburg Gmbh Reagents for assays for mycophenolic acid
US6171801B1 (en) 1996-07-18 2001-01-09 Dade Behring Marburg Gmbh Methods for releasing a ligand from a complex
US6887669B1 (en) 1996-07-18 2005-05-03 Dade Behring Marburg Gmbh Reagents for assays for ligands

Also Published As

Publication number Publication date
JPS58501073A (ja) 1983-07-07
EP0082156A1 (fr) 1983-06-29
EP0082156A4 (fr) 1983-12-01

Similar Documents

Publication Publication Date Title
EP0361470B1 (fr) Méthode pour la détermination de l'activité de peroxydase utilisant la chémiluminescence
US4243749A (en) Immunoassay employing an enzyme label
CA1039184A (fr) Dosage radioimmunologique de la digoxine en phase solide
US4476229A (en) Substituted carboxyfluoresceins
JP2952013B2 (ja) 不均一系イムノアッセイ
EP0722087B1 (fr) Systeme de mesure fonctionnant avec du sang entier
NO152955B (no) Reagens for bestemmelse av et immunologisk aktivt materiale
US4299812A (en) Immunoassay of thyroxine in neonates using dried blood samples
US4180556A (en) Pretreatment method for carcinoembryonic antigen assay
US4522922A (en) Soluble assay
US4052504A (en) Assay for thyroxine binding globulin
JPH0670629B2 (ja) 免疫反応の反応成分を測定するための方法及び試薬
US4069305A (en) I125 Imidazole steroid derivatives
US5998156A (en) Color developing method, enzyme immunoassay using the color developing method, and immunochromatography incorporating the enzyme immunoassay
US4788136A (en) Diagnostic immunoassay by solid phase separation for digoxin
JP3348250B2 (ja) 遊離種アナライト検定
Dechaud et al. New approach to competitive lanthanide immunoassay: time-resolved fluoroimmunoassay of progesterone with labeled analyte.
WO1983000147A1 (fr) Analogues de l'acide 8-anylino naphtalene-1-sulfonique
AU552573B2 (en) 8-anilino naphthalene-1- sulphonic acid analogues
US5196349A (en) Immunoassays for thyroid hormones using thyroglobulin
US4548908A (en) Competitive immunofluorescence assay and test kit
CA2094397C (fr) Agents homobifonctionnels pour le couplage d'enzymes et autres substances a des anticorps et autres substances
US5342788A (en) Method and standard solution for the determination of thyroxine (T4) or triiodothyronine (T3)
EP0253270B1 (fr) Méthode pour immunoessai diagnostique par séparation en phase solide
EP0108136B1 (fr) Analyse d'immunofluorescence competitive et trousse de test

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU JP US

Designated state(s): AU JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): DE FR GB NL SE

Designated state(s): DE FR GB NL SE

WWE Wipo information: entry into national phase

Ref document number: 1982901830

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1982901830

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1982901830

Country of ref document: EP